Goodman Group’s AI Bet Faces an ASX Reality Check After Stock Slips

Goodman Group’s AI Bet Faces an ASX Reality Check After Stock Slips

June 8, 2026

Sydney, June 9, 2026, 04:05 AEST

Goodman Group shares head into Tuesday’s ASX restart at A$31.10, after a soft finish before the long weekend left investors weighing its fast-growing data-centre pipeline against delivery and funding risk. The stock last closed down 0.38%, according to the ASX company page.

The timing matters. There was no Monday cash-market trading to reset the price, with the ASX listing King’s Birthday on June 8 as a closed, no-settlement session.

Goodman lost about 1.8% over the week, while the S&P/ASX 200 fell 0.70% on Friday to 8,625.10 and was down roughly 1.2% for the week. The S&P/ASX 200 is the main institutional benchmark, meaning the yardstick used by many funds to judge Australian large-cap share performance.

The stock’s next move now rests less on the broad AI story and more on proof. Goodman said in its Q3 update that development work in progress, or the estimated value of projects being built, was A$14.5 billion at March 31 and was expected to reach about A$18 billion by June 2026; data centres accounted for 73% of that work, and its “power bank” — electricity capacity tied to current and future data-centre sites — stood at 6.4 gigawatts. Goodman

Chief Executive Greg Goodman said customer talks were advancing as supply stayed constrained by grid capacity, water, site complexity and capital intensity. He also said “equity capital is becoming more selective,” and the company remained on track for at least 9% operating earnings per security growth in FY26; operating EPS is a per-security profit measure based on underlying operations. Goodman

That was not enough for every investor. The Australian reported last week that Goodman’s securities fell 2.8% after the company reiterated, rather than lifted, guidance; Bell Potter analyst Andy MacFarlane said the group had repeated guidance while lifting its power bank by 7% to 6.4GW.

The peer read-through is mixed but relevant. NEXTDC, the ASX-listed data-centre operator and a key name investors use to track digital infrastructure demand, last closed at A$15.860, down 3.11%, showing the AI infrastructure trade has not been immune to selling.

Goodman is not just a data-centre punt. Its own site lists a A$87.1 billion total portfolio, 15 countries and 6.4GW of total power, and describes the group as providing logistics and data-centre infrastructure for the digital economy.

But the downside case is plain enough. If customer contracts take longer, power costs rise, or construction costs move against the group, the market could keep treating Goodman more like a developer taking execution risk than a defensive landlord. Its update also flagged negative rental reversion in China, meaning some rents there are resetting below previous levels, even as the wider portfolio stayed positive.

The week ahead is about evidence. Investors will be looking for customer commitments, capital-partner progress in Australia, or any fresh ASX filing that turns the data-centre pipeline into contracted income.

Until then, A$31.10 is the marker. The stock’s first trades after the holiday break will say whether investors still want to pay up for Goodman’s AI-linked growth, or whether they want clearer proof before pushing it back higher.

Mateusz Ługowik

Mateusz Ługowik is a senior markets reporter at Bez-kabli.pl, specializing in technology stocks, artificial intelligence and global financial markets. A graduate of the University of Gdańsk, he previously worked in investment research and market analysis. His coverage helps readers understand the key trends, companies and innovations influencing investors worldwide.

Stock Market Today

  • ResMed Up 3% on ASX but Still 31% Lower Year Over Year
    July 28, 2026, 12:53 AM EDT. ResMed Inc shares rose 3% on the ASX to $28.77, but the stock is still down 31% for the year as the healthcare sector heads into a weaker 2026. The company posted an 11% revenue jump to $1.4 billion in Q3, but that fell short of forecasts and led to a selloff. Pressure from macro conditions and worries about GLP-1 weight-loss drugs are weighing on ResMed. Still, revenue and margins are both growing, free cash flow is solid. Analyst views are mixed, though the average target suggests up to 63% upside. The stock screens as oversold and may be undervalued, but hitting last year's highs by mid-2025 looks uncertain.